Curis Provides Fourth Quarter 2025 Business Update

March 20, 2026 - 01:43

Curis, Inc., a biotechnology firm, has provided a comprehensive business update for the final quarter of 2025, highlighting advancements in its clinical pipeline and detailing its financial position. The company's primary focus remains on emavusertib (CA-4948), an investigational oral treatment targeting IRAK4, a key protein in cancer cell survival and proliferation.

Recent developments underscore the company's strategic direction. Curis announced the completion of patient enrollment in the ongoing TakeAim Leukemia trial, a significant milestone for evaluating emavusertib in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The company is actively preparing for anticipated interactions with regulatory agencies regarding this program.

Financially, Curis reported its cash, cash equivalents, and investments as of December 31, 2025. Management stated that these resources are expected to fund planned operations into a specified future period, providing a runway for continued development. The update also included summarized financial results for the quarter and full year, reflecting the company's investment in its core research and development activities.

Company leadership expressed optimism about the potential of emavusertib and reaffirmed their commitment to addressing unmet needs in oncology. The progress in key clinical trials represents a central part of Curis's mission to develop novel therapies for patients fighting cancer. Further data disclosures and regulatory updates are expected as the clinical programs advance.